Part 3/9:
Remarkable Results in Pain and Inflammation Markers
Within just one week, the high-dose group exhibited a 12% reduction in pain scores alongside noticeable improvements in joint mobility. By the end of 90 days, the results were even more striking:
Pain alleviation: Up to 65% reduction in pain scores, especially in the high-dose group.
Functional gains: Enhanced joint flexibility, stiffness reduction, and better movement.
Inflammation marker (MMP3) reduction: Nearly half of this enzyme—specifically, 46% in the high-dose group—was eliminated. MMP3 is directly involved in cartilage breakdown and inflammation, so its reduction signals a profound dampening of joint inflammation.